SciVision Biotech Inc (1786) - Total Assets
Based on the latest financial reports, SciVision Biotech Inc (1786) holds total assets worth NT$2.61 Billion TWD (≈ $82.23 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of SciVision Biotech Inc for net asset value and shareholders' equity analysis.
SciVision Biotech Inc - Total Assets Trend (2009–2024)
This chart illustrates how SciVision Biotech Inc's total assets have evolved over time, based on quarterly financial data.
SciVision Biotech Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
SciVision Biotech Inc's total assets of NT$2.61 Billion consist of 49.5% current assets and 50.5% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 30.0% |
| Accounts Receivable | NT$174.02 Million | 7.4% |
| Inventory | NT$72.23 Million | 3.1% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$1.68 Million | 0.1% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2009–2024)
This chart illustrates how SciVision Biotech Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of SciVision Biotech Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SciVision Biotech Inc's current assets represent 49.5% of total assets in 2024, an increase from 13.0% in 2009.
- Cash Position: Cash and equivalents constituted 30.0% of total assets in 2024, up from 0.5% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2009.
- Asset Diversification: The largest asset category is accounts receivable at 7.4% of total assets.
SciVision Biotech Inc Competitors by Total Assets
Key competitors of SciVision Biotech Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
iRay Technology Co Ltd
SHG:688301
|
China | CN¥11.33 Billion |
|
Nanosonics Ltd
AU:NAN
|
Australia | AU$272.48 Million |
|
Jiangsu Nanfang Medical
SHG:603880
|
China | CN¥993.46 Million |
|
MEDIMI AB AK
F:79T
|
Germany | €1.70 Million |
|
Ansell Ltd
AU:ANN
|
Australia | AU$3.32 Billion |
|
SDI Ltd
AU:SDI
|
Australia | AU$141.20 Million |
|
Austco Healthcare Ltd
AU:AHC
|
Australia | AU$91.07 Million |
|
Trajan Group Holdings Ltd
AU:TRJ
|
Australia | AU$192.32 Million |
SciVision Biotech Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.58 | 8.24 | 4.55 |
| Quick Ratio | 7.12 | 7.62 | 4.17 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$1.18 Billion | NT$893.73 Million | NT$431.84 Million |
SciVision Biotech Inc - Advanced Valuation Insights
This section examines the relationship between SciVision Biotech Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.79 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | 9.0% |
| Total Assets | NT$2.35 Billion |
| Market Capitalization | $135.56 Million USD |
Valuation Analysis
Below Book Valuation: The market values SciVision Biotech Inc's assets below their book value (0.06x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: SciVision Biotech Inc's assets grew by 9.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for SciVision Biotech Inc (2009–2024)
The table below shows the annual total assets of SciVision Biotech Inc from 2009 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$2.35 Billion ≈ $74.18 Million |
+8.99% |
| 2023-12-31 | NT$2.16 Billion ≈ $68.06 Million |
+2.95% |
| 2022-12-31 | NT$2.10 Billion ≈ $66.11 Million |
-7.24% |
| 2021-12-31 | NT$2.26 Billion ≈ $71.26 Million |
+19.63% |
| 2020-12-31 | NT$1.89 Billion ≈ $59.57 Million |
+1.55% |
| 2019-12-31 | NT$1.86 Billion ≈ $58.66 Million |
+9.79% |
| 2018-12-31 | NT$1.70 Billion ≈ $53.43 Million |
+8.48% |
| 2017-12-31 | NT$1.56 Billion ≈ $49.25 Million |
+15.18% |
| 2016-12-31 | NT$1.36 Billion ≈ $42.76 Million |
+26.51% |
| 2015-12-31 | NT$1.07 Billion ≈ $33.80 Million |
-1.75% |
| 2014-12-31 | NT$1.09 Billion ≈ $34.40 Million |
-3.29% |
| 2013-12-31 | NT$1.13 Billion ≈ $35.57 Million |
+133.62% |
| 2012-12-31 | NT$483.28 Million ≈ $15.23 Million |
+19.66% |
| 2011-12-31 | NT$403.87 Million ≈ $12.72 Million |
+81.13% |
| 2010-12-31 | NT$222.97 Million ≈ $7.02 Million |
+18.35% |
| 2009-12-31 | NT$188.40 Million ≈ $5.94 Million |
-- |
About SciVision Biotech Inc
SciVision Biotech Inc. develops and manufactures medical-grade hyaluronic acid products in Taiwan. The company offers synovial fluid supplements, facial dermal implants, absorbable adhesion barriers, and intravesical instillation products. It also involved in international trade; wholesale of medical equipment and cosmetics; and provides management advisory services. SciVision Biotech Inc. was fo… Read more